Developments in traceability requirements around the globe

Activities in WHO

C. Micha Nübling
Blood Products and related Biologicals (BLD)
Technologies, Standards and Norms (TSN)



WHO's Normative Work

WHO mandated by Member States to set global standards

- Written standards
 - International Pharmacopeia
 - INN
 - GMP
 -

Measurement standards

- Vaccines
- Blood products
- In vitro diagnostics
- **–**



WHO International Standards

Measurement Standards

- Biological materials for standardization of diagnostic assays
- Globally available
- Representative for target materials
 - analyte: species, strain
 - matrixes
- Commutable to routine test samples
 - no introduction of bias



WHO International Standards

- "High" concentration of target
 - to cover linear range of quantitative assays
 - to enable calibration of secondary standards
 - to enable preparation of working reagents, run controls

- Lyophilization
 - worldwide shipping at ambient conditions

- Proof of suitability in international collaborative study
 - harmonisation of assays



Need for Reference Materials Inter-assay variation in proficiency testing

Virus	International Standard	SD range of geometric mean (log10)	% of commercial assays
HIV	Y	0.17 - 0.27	> 95%
HCV	Y	0.20 - 0.30	> 95%
HBV	Y	0.30 - 0.45	~ 50%
BKV	N	0.5 - 0.6	~ 30%
HSV	N	0.6 - 0.7	< 15%
EV	N	>1.0	< 10%

Expert Committee for Biological Standardization (ECBS)

Committee establishing WHO standards for biologicals

- Written standards, e.g. WHO Guidelines
- Biological reference preparations, e.g. WHO Intern. Standards
- Blood products, in vitro diagnostics
- Vaccines and biotherapeutics
- Cell therapy products



Report of WHO CC Meeting (July 02/03, 2015)

WHO Collaborating Centers for Blood Products and IVDs

- FDA CBER, USA
- NIBSC, UK
- PEI, DE

Priorisation of new standardization projects,

Update on ongoing projects

Discussion of issues



WHO Collaborating Centers for Blood Products and IVDs

Priorisation of new standardization projects input from...

- WHO MSs, WHO CCs
- Health organisations and projects
- IVD industry

agreed proposals presented at ECBS for endorsment



66th ECBS New Projects endorsed

```
WHO International Standards for....
....Ebola RNA, antiEbola
....VZV DNA
....Plasmodium falciparum antigen
....Plasmodium vivax DNA
....Trypanosoma cruzi DNA
WHO International Reference Panels for...
....antiHEV: HEV genotypes
.....HIV p24: HIV subtype VLPs
....antiBabesia microtii
.....KRAS codons 12,13
WHO Repository for transfusion-relevant bacteria, eythrocyte-derived
```



WHO Collaborating Centers for Blood Products and IVDs

Update on ongoing projects

discussion of collaborative study outcomes

presentation at ECBS for establishment



66th ECBS

Biological Reference Preparations established

New WHO International Standards for....

....BK DNA, JC DNA

....Insulin C peptide

....several replacement WHO Iss

New WHO International Reference Reagents for...

....antiEbola

....Ebola RNA

....antiA, antiB

WHO Repository for transfusion-relevant bacteria, platelet-derived

.....extension by 10 further bacteria strains



Report of WHO CC Meeting (July 02/03, 2015)

WHO Collaborating Centers for Blood Products and IVDs

Discussion of issues

problems encountered during standardization projects

scientific updates



WHO Collaborating Centers for Blood Products and IVDs

Standardization issues

varying stability of viral RNA in some preparations

HEV

stool- versus plasma derived virus; stabilizers

HCV

residual moisture



WHO Collaborating Centers for Blood Products and IVDs

Standardization issues

Commutability of WHO International Standards

April 2013: WHO Consultation on Commutability of WHO Biological Reference Preparations for of Infectious Markers

Evaluation of commutability part of collaborative studies and post-establishment



draft WHO Guideline on
 Calibration of secondary standards for IVD

covering nucleic acids, antigens, antibodies

advice on statistics, number of assays, matrixes etc

further discussion by different stakeholders

IVD manufacturers, QC material providers PTS organizers SOGAT

adoption planned for ECBS 2016



Standardization of biotherapeutics, e.g. mAbs


New concept for reference materials?

for control of the bio-assay, or

reflecting the target material (e.g. mAb)

WHO consultations





WHO Biological Standardization Program www.who.int/bloodproducts/catalogue/en/

Thank you

